HiFiBiO Therapeutics’ Post

🎉 Breakthrough in Cancer Treatment: Bispecific T Cell Engager (BiTEs) The outlook for extensive small cell lung cancer (SCLC) is generally poor. Without treatment, survival rates are typically 2–4 months. Treatment can extend this to an average of 7–11 months. Researchers had achieved a significant milestone in fight against this disease. Yesterday US (FDA) granted accelerated approval to Tarlatamab for patients with extensive-stage small cell lung cancer (SCLC). Let me explain the science here, T-cells also called as T-Lymphocytes can destruct tumor cells in lungs. The challenge is how T-cells find specific tumor cells and start the destruction process. And here comes Tarlatamab, a bispecific T cell engager (As name suggest, BiTEs bring two specific monoclonal antibodies fragment, connected with a peptide linker). One protein part specifically bind to CD3 on surface of T-cell and another with DLL3 a targeted ligand on SCLC cancer cells. This way T-cells get activated and connected with SCLC cancer cells and start the process of destruction. Congratulations to Team Amgen, all oncology researchers, and peptide chemists around the globe on this great milestone. We are one step closer in our fight against cancer and to saving more lives! #CancerResearch #Oncology #Biotech #HealthcareInnovation #FDAApproval #Amgen

We are happy to present a poster at the 14th World Antibody Drug Conjugate summit in San Diego October 17-18th 2023. https://worldadc-usa.com/, in addition to our exhibit. The poster is entitled "Development of competing and non-competing fully human internalizing anti-Her2 monoclonal antibodies". This describes the work accomplished by our dedicated Precision Antibody team to develop in 60 days from start of immunization to the selection of functional single clone, several fully human anti-Her2 monoclonal antibodies with their characterization as antibody drug conjugates to inhibit Her-2 overexpressing breast cancer cells growth. We’ll be pleased to provide a copy of the poster. #antibody, #Her2 #breast cancer #internalizing #fully human antibody

Happy Wednesday all! Hot off the presses - check out our newly released NY-ESO-1 (c259) TCR-T Cells #78990 https://lnkd.in/gVd_MkpA Background: NY-ESO-1 is an important tumorigenic marker present in malignant cells. Normally only expressed in embryonic testis, this highly immunogenic protein is re-expressed in multiple myeloma, non-small cell lung carcinoma (NSCLC), breast and ovarian cancer, making it a promising candidate antigen for cancer immunotherapy. Several NY-ESO-1-directed therapies are being developed including cancer vaccines, anti-NY-ESO-1 adoptive cell therapy, and NY-ESO-1-specific TCR-T cell therapy in combination with checkpoint inhibitors, and thus the NY-ESO-1 (c259) TCR-T Cells are an excellent tool for related cancer drug discovery research. Please reach out to me with any questions or for a quote! #drugdiscovery #cartcelltherapy #adoptivecelltherapy #cancerresearch #immunooncology #immunotherapy #scientificresearch

Is it possible to create targeted and personalised immunotherapies that fight cancer at the molecular level?        Prescient Therapeutics, a clinical-stage oncology biotech company, is partnering with La Trobe University and the Baker Heart and Diabetes Institute to find out.          “Our partnership with Prescient Therapeutics is helping to develop next-generation, personalised immunotherapies,” explains Associate Professor David Greening from the Baker Institute.         Immunotherapy is a type of immune-boosting cancer treatment that uses substances made in the body, or a laboratory, to find and destroy cancer cells.           “We’re progressing something called Chimeric Antigen Receptor (CAR) T-cell therapy. It involves collecting T cells from people’s blood and re-engineering them to carry structures on their surface, which make the treatment more targeted and bespoke,” Associate Professor Greening says.          “These structures essentially train the T-cells to target and attack cancers which the body may otherwise have missed.”      Prescient Therapeutics’ Senior VP for Scientific Affairs, Associate Professor Rebecca Lim, believes that the potential impact of this research is significant.   “Ultimately, this work will allow the design of more effective CAR-T therapies,” she says. “This has potentially profound implications for personalised cancer treatment.”   Read more: https://bit.ly/490N5VV   #LaTrobeAgricultureBiomedicineAndEnvironment #BakerInstitute #PrescientTherapeutics #Cancer

New!🎆 #Auranofinrepurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in #patientderivedorganoids, with potentiated efficacy by AKT inhibition ----------------- This study by Christophe Deben explores the repurposing of Auranofin (AF), an anti-rheumatic drug, for treating non-small cell lung cancer (NSCLC) adenocarcinoma and pancreatic ductal adenocarcinoma (PDAC). Drug repurposing in oncology offers a cost-effective and time-efficient approach to developing new cancer therapies. This research focuses on evaluating AF's selective cytotoxicity against cancer cells, identifying RNAseq-based biomarkers to predict AF response, and finding the most effective co-therapeutic agents for combination with AF. See here👇 https://lnkd.in/dwcwf47c #PancreaticCancer #LungCancer IFO - Istituto Nazionale Tumori Regina Elena - Istituto Dermatologico San Gallicano

Arguably, PD1/PDL1-directed antibodies are one of the most significant advancements in oncology in recent decades. However, the quest for small molecule PD1/PDL1 antagonists is gaining momentum. The rationale behind this pursuit stems from the fact that only a subset of cancer patients derive benefit from PD1/PDL1-directed antibodies. In many cases, the therapeutic effects are not long-lasting, and patients may experience disease progression. Additionally, these treatments can entail significant side effects. Our team contributed to this field by solving and publishing the first human PD1/PDL1 co-crystal structure (Zak et al., Structure, 2015), as well as describing the first co-crystal structure of a small molecule (developed by BMS) that effectively antagonizes PD1/PDL1 (Zak et al., Onco Targets Ther, 2016). While several small molecules are currently being tested in clinical trials, the understanding of their exact mechanisms of action remains limited. To shed further light on this emerging area, we have published our new paper titled ‘1,5-Disubstituted Tetrazoles as PD-1/PD-L1 Antagonists’. This work expands our understanding of small molecule inhibitors in the context of PD1/PDL1 interaction, a critical pathway in cancer immunotherapy. Also featured is a novel co-crystal structure of a small molecule with the PD-L1 dimer. We invite you to read our latest findings, which are freely available at: https://lnkd.in/e9STCiF9. #Immune_therapy #oncology #PD1 #PDL1 #medchem #checkpoint_inhibitor #tetrazol #MCR #isocyanide #crystal_structure #CATRIN #IMTM

In this week’s #MAbMonday spotlight, we’d like to recognize the work on Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cells. https://hubs.la/Q02drXJl0 The team stated, "This study demonstrates the utility of the Luminex(R) multiplex system as an efficient and comprehensive approach to study different aspects of molecular roles of these RTKs. Importantly, the study provides proof-of-concept for the utility of the multiplex microbead immunoassay approach for potential use inefficient, robust, and rapid screening of drugs, particularly those targeting functional aspects of these potent signaling molecules. In addition, the assays described here may be useful for cancer diagnostics and monitoring efficacy of therapy targeting the ErbB family of RTKs." 👇Featured product👇 Anti-Human EGFR (External Domain) – Biotin: https://hubs.la/Q02drR4-0 #Leinco #ReproducibleScience #Immunology

Check out my latest publication: https://lnkd.in/gtXDCBwp The studies described in this manuscript focused on the immunomodulatory effects of the triterpenoid CDDO-Me in a murine model of established Kras-driven lung cancer, alone and in combination with the chemotherapeutic drugs carboplatin and paclitaxel. CDDO-Me favorably modulated the immune microenvironment, protected mice from chemotherapy-related toxicity, and the combination of CDDO-Me plus chemotherapy was significantly more effective in reducing tumor burden compared to either agent alone. My current studies are further characterizing the interaction between lung cancer cells and the immune cells within their environment, specifically focusing on how Nrf2 activity in both of these cell populations affects cell behavior.

Lipid nanoparticles (LNPs) become a valuable drug delivery system for cancer drugs. In this interesting review article you can find out how they can improve lung cancer treatment and which challenges remain. Click the picture to find out more about it! #lungcancer #cancerresearch #lipidnanoparticles #oncology #medicaleducation

Transforming Cancer Treatment with Propanc Biopharma's Differentiation Therapy   Innovating Beyond Traditional Methods   At Propanc Biopharma, we're redefining cancer treatment. Our Pancreatic Proenzyme Therapy is a leap forward, focusing on cell differentiation rather than cell destruction. This approach redirects cancer cells back to their normal functions, reducing harm to healthy cells and minimizing side effects.   Why Our Approach Stands Out   Targeted Action: Our therapy specifically inhibits the Epithelial-Mesenchymal Transition (EMT), crucial in cancer metastasis.   Reduced Side Effects: Unlike conventional treatments, our method spares healthy cells, focusing solely on transforming cancer cells into non-proliferative cells.   Innovative Mechanism: We're turning the tables on cancer by encouraging malignant and cancer stem cells to undergo terminal differentiation, thus reducing their malignancy.   A Step Towards Safer, More Effective Cancer Care   Our therapy represents a new horizon in oncology, offering effective treatment while aligning with the body's natural processes.    Join us in our journey towards a future where cancer treatment is as safe as it is successful.   #PropancBiopharma #CancerCare #Innovation #HealthTech Propanc Biopharma, Inc. (OTCQB:PPCB)